$210M 'COMFORT' Zone
JAKs Are Better: Incyte Draws Novartis, Pfizer Face-off Next?
By Randy Osborne
The deal step taken by Gleevec-experienced Novartis AG - probably Incyte Corp.'s most logical big-pharma partner outside the U.S. for its Phase III JAK1/2 inhibitor against myelofibrosis - may not have surprised many, but adding another, earlier-stage compound in the cMET inhibitor class made a nice bonus. (BioWorld Today)